187 related articles for article (PubMed ID: 16514710)
1. Beyond Gleevec--the next generation in CML.
Fricker J
Eur J Cancer; 2006 Feb; 42(3):275. PubMed ID: 16514710
[No Abstract] [Full Text] [Related]
2. Molecular response in CML: where is the bar?
Baccarani M; Soverini S
Blood; 2014 Jul; 124(4):469-71. PubMed ID: 25061165
[TBL] [Abstract][Full Text] [Related]
3. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
[No Abstract] [Full Text] [Related]
4. Leukemia cells fall on their swords.
Rutherford A
Trends Mol Med; 2001 Apr; 7(4):149. PubMed ID: 11286930
[No Abstract] [Full Text] [Related]
5. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.
Holtz MS; Bhatia R
Leuk Lymphoma; 2004 Feb; 45(2):237-45. PubMed ID: 15101707
[TBL] [Abstract][Full Text] [Related]
6. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Quintás-Cardama A; Kantarjian H; Cortes J
Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640
[No Abstract] [Full Text] [Related]
7. STI571 (Gleevec) as a paradigm for cancer therapy.
Druker BJ
Trends Mol Med; 2002; 8(4 Suppl):S14-8. PubMed ID: 11927282
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate.
Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
[No Abstract] [Full Text] [Related]
9. Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors.
Minami Y; Abe A; Minami M; Kitamura K; Hiraga J; Mizuno S; Ymamoto K; Sawa M; Inagaki Y; Miyamura K; Naoe T
Leukemia; 2012 Sep; 26(9):2142-3. PubMed ID: 22425893
[No Abstract] [Full Text] [Related]
10. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
Popovici C; Cailleres S; David M; Lafage-Pochitaloff M; Sainty D; Mozziconacci MJ
Leuk Lymphoma; 2005 Sep; 46(9):1375-7. PubMed ID: 16109618
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of imatinib therapy after achieving a molecular response.
Cortes J; O'Brien S; Kantarjian H
Blood; 2004 Oct; 104(7):2204-5. PubMed ID: 15377577
[No Abstract] [Full Text] [Related]
12. Gleevec: tailoring to fit.
May TS
Drug Discov Today; 2003 Mar; 8(5):188-9. PubMed ID: 12634004
[No Abstract] [Full Text] [Related]
13. Chronic myeloid leukemia. Sceptical scientists.
Druker BJ
Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
[No Abstract] [Full Text] [Related]
14. Gleevec resistance: lessons for target-directed drug development.
Daley GQ
Cell Cycle; 2003; 2(3):190-1. PubMed ID: 12734421
[No Abstract] [Full Text] [Related]
15. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
Bazeos A; Marin D; Reid AG; Gerrard G; Milojkovic D; May PC; de Lavallade H; Garland P; Rezvani K; Apperley JF; Goldman JM; Foroni L; Khorashad JS
Leukemia; 2010 Jun; 24(6):1243-5. PubMed ID: 20445576
[No Abstract] [Full Text] [Related]
16. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.
Aloisi A; Di Gregorio S; Stagno F; Guglielmo P; Mannino F; Sormani MP; Bruzzi P; Gambacorti-Passerini C; Saglio G; Venuta S; Giustolisi R; Messina A; Vigneri P
Blood; 2006 Feb; 107(4):1591-8. PubMed ID: 16249386
[TBL] [Abstract][Full Text] [Related]
17. Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy.
Soderquist C; Bagg A
Blood; 2014 Oct; 124(15):2463. PubMed ID: 25436260
[No Abstract] [Full Text] [Related]
18. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of chronic myelogenous leukemia by using imatinib].
Jinnai I
Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1819-24. PubMed ID: 16223141
[No Abstract] [Full Text] [Related]
20. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
